C
ELVN icon

Covestor’s Enliven Therapeutics ELVN Stock Holding History

Covestor’s Portfolio ELVN Stock Details ELVN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1K Buy
15
+9
+150% +$382 ﹤0.01% 2129
2026
Q1 		$0 Hold
6
– – ﹤0.01% 2380
2025
Q4 		$0 Sell
6
-11
-65% -$219 ﹤0.01% 2368
2025
Q3 		$0 Buy
17
+11
+183% +$222 ﹤0.01% 2392
2025
Q2 		$0 Hold
6
– – ﹤0.01% 2333
2025
Q1 		$0 Hold
6
– – ﹤0.01% 2348
2024
Q4 		$0 Hold
6
– – ﹤0.01% 2351
2024
Q3 		$0 Hold
6
– – ﹤0.01% 2341
2024
Q2 		$0 Buy
6
+5
+500% +$105 ﹤0.01% 2352
2024
Q1 		$0 Hold
1
– – ﹤0.01% 2352
2023
Q4 		$0 Hold
1
– – ﹤0.01% 2266
2023
Q3 		$0 Hold
1
– – ﹤0.01% 2242
2023
Q2 		$0 Buy
+1
New +$20 ﹤0.01% 2253

Other funds holding ELVN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return

Covestor's ELVN Position: Q2 2026 in Review

Covestor increased its Enliven Therapeutics (ELVN) stake by 150% in Q2 2026, buying an estimated $382 and bringing the position to 15 shares worth $1K. The position accounts for ﹤0.01% of the portfolio, ranked #2129.

Covestor first reported a position in ELVN in Q2 2023 and has held it in 13 quarters since. 212 funds tracked by Wall St. Rank hold ELVN as of Q2 2026.

  • Covestor held 15 shares of Enliven Therapeutics worth $1K as of Q2 2026.
  • Covestor bought 9 Enliven Therapeutics shares in Q2 2026, an estimated $382.
  • Enliven Therapeutics made up ﹤0.01% of Covestor's portfolio in Q2 2026, its #2129 holding.
  • Covestor first reported a position in Enliven Therapeutics in Q2 2023 and has held it in 13 quarters since.
  • 212 funds tracked by Wall St. Rank held Enliven Therapeutics as of Q2 2026.

Based on Covestor's 13F filing for Q2 2026, filed 7 Aug 2026.